Skip to main content
Berry Genomics Co.,Ltd logo

Berry Genomics Co.,Ltd — Investor Relations & Filings

Ticker · 000710 ISIN · CNE000000PN7 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,009 across all filing types
Latest filing 2020-07-22 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 000710

About Berry Genomics Co.,Ltd

https://www.berrygenomics.com

Berry Genomics Co.,Ltd. is a biotechnology enterprise specializing in clinical genomics and genetic testing services. The company focuses on the research, development, and commercialization of genomic technologies for clinical applications. Its core portfolio includes non-invasive prenatal testing (NIPT), utilizing high-throughput sequencing to screen for chromosomal abnormalities. Beyond reproductive health, the company provides genomic solutions for oncology diagnostics, including early cancer screening and companion diagnostics, as well as testing for hereditary diseases. Berry Genomics leverages advanced sequencing platforms and proprietary bioinformatics pipelines to deliver precision medicine tools to healthcare providers and research institutions. The company is recognized for its role in the clinical application of Next-Generation Sequencing (NGS) and its extensive genomic databases used to enhance diagnostic accuracy and therapeutic outcomes.

Recent filings

Filing Released Lang Actions
独立董事提名人声明
Board/Management Information Classification · 95% confidence The document is a public statement by a nominator regarding the nomination of an independent director candidate for the company's board. It details the qualifications, compliance with regulatory requirements, and declarations related to the nominee's eligibility and independence. There is no financial data, no discussion of financial results, no mention of shareholder voting results, or any other financial or operational report. The document is an announcement related to board/management information, specifically about a nomination for the board of directors. Therefore, the appropriate classification is Board/Management Information (MANG). The document length (6457 characters) supports it being a full statement rather than a brief announcement or notice.
2020-07-22 Chinese
关于全资子公司检测试剂盒通过注册检验的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the registration inspection approval of a diagnostic reagent kit by a wholly-owned subsidiary. It contains no financial statements, no management discussion of financial results, no voting results, no executive changes, no earnings data, and no regulatory certifications. The document is relatively short (1054 characters) and focuses on product registration and regulatory compliance information. It is not a report itself but an announcement about a product registration inspection result. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-07-16 Chinese
2020年半年度业绩预告
Regulatory Filings Classification · 95% confidence The document is titled as a '2020 Half-Year Performance Forecast' and covers the period from January 1, 2020 to June 30, 2020. It provides estimated financial results, including net profit and earnings per share, but explicitly states that the data is unaudited and preliminary. It also explains reasons for performance changes and mentions that detailed financial data will be disclosed in the 2020 half-year report. The document is short (1286 characters) and serves as a performance forecast announcement rather than a full interim or quarterly report containing actual financial statements or substantive financial data. Therefore, it is best classified as a Regulatory Filing (RNS) since it does not contain the full interim report itself but is an announcement related to performance forecasts.
2020-07-14 Chinese
关于对深圳证券交易所2019年年报问询函的回复公告
Regulatory Filings Classification · 95% confidence The document is a detailed reply to an inquiry letter from the Shenzhen Stock Exchange regarding the company's 2019 annual report. It contains extensive financial data, audit procedures, and explanations related to the 2019 annual report, including performance commitments, revenue breakdowns, related party transactions, and audit conclusions. The presence of detailed financial figures, audit opinions, and explanations about the annual report's content indicates this is a regulatory response document related to the annual report, not the annual report itself. The document is lengthy (15,000 characters) and contains substantive financial and audit information, but it is a reply to an inquiry about the annual report, not the annual report itself. According to the classification rules, such a document is best classified as a Regulatory Filing (RNS) because it is a regulatory response and does not constitute the full annual report (10-K).
2020-07-03 Chinese
关于对公司的年报问询函的回复
Regulatory Filings
2020-07-03 Chinese
关于回购股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is a progress announcement regarding the company's share repurchase program. It details the number of shares repurchased, the price range, total amount spent, compliance with regulatory rules, and future plans for the buyback. It references a previously disclosed repurchase plan and provides updates on the repurchase activity up to June 30, 2020. The document is relatively short (1534 characters) and focuses solely on the progress of the share buyback, not on financial results or other report types. This fits the definition of a Transaction in Own Shares (POS) filing, which reports on the company's buyback or sale of its own shares.
2020-07-03 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.